Australian rapid diagnostic blood test company, Atomo Diagnostics has secured a deal with New Delhi-based DIVOC Laboratories, to sell its TGA approved and CE Marked AtomoRapid COVID-19 antibody tests in the Indian market.
Atomo will initially provide 77,000 antibody test kits, upon DIVOC obtaining product registration approval for professional use, which is anticipated to be received in Q2 FY21.
Under the agreement, NABL- accredited DIVOC will distribute the test, with significant potential for distribution to government, corporate, lab to lab, and importantly through an established home visit network that will enable at-home testing, supported by medical professionals.
- Advertisement -